MIT community members are welcome to attend a presentation by Alice Shaw, MD, PhD, our first clinical investigator and currently the global head of translational clinical oncology at Novartis Institutes for BioMedical Research. Before her transition to Novartis, Dr. Shaw’s research at MGH focused on molecularly defined subsets of non-small cell lung cancer (NSCLC) and their mechanisms of resistance to targeted therapies, helping to develop four FDA approved therapies for oncogene-driven NSCLC.
